{
  "articles": [
    {
      "path": "about.html",
      "title": "About this site",
      "description": "This website hosts various analyses done on NF related data available on the [NF Data Portal](www.nfdataportal.org)",
      "author": [],
      "contents": "\n\n\n\n",
      "last_modified": "2021-11-04T17:44:08-07:00"
    },
    {
      "path": "DRUID.html",
      "title": "DRUID analysis of JHU Biobank data",
      "description": "DRUID analysis of JHU Biobank data",
      "author": [
        {
          "name": "Jineta Banerjee",
          "url": {}
        }
      ],
      "date": "`r Sys.Date()`",
      "contents": "\n\n\n\nPublicly available data from JHU Biobank\nWe used the publicly available JHU Biobank RNASeq data stored in project : syn20812185 for this analysis.\n\n\n\nWe then used TMM normalization to prepare the dataset for differential gene expression analysis.\n\n\n\nÂ \nDifferential gene expression analysis in samples:\nWe used limma-edgeR based analysis to find differentially expressed genes in the TMM normalized dataset.\nA point to note:\nAll MPNST samples except one are males while all PNF samples except one are femmales. So there may be a sex related effect on the analysis that we dont have a good way to mitigate.\nThe number of MPNST samples are extremely limited (n=4), so these results should be evaluated with more samples when possible\nThe plot below shows genes that are significantly overexpressed in MPNST compared to PNF (logFC > 4) in red. The dots in blue refer to genes that are significantly underexpressed in MPNST compared to PNF (logFC < -4). The thresholds of fold change have been arbitrarily chosen for ease of visualization in the volcano plot shown below.\n\n\n\nFigure 1: Differential expression of genes in MPNST and pNF tumor types. Above shows a volcano plot highlighting significantly upregulated genes in red and downregulated genes in blue\n\n\n\nPredicting drug candidates based on significant DEGs using DRUID:\nWe then took the subset of genes that were significantly differentially expressed between MPNST and pNF tumor types and used DRUID to enrich candidate drugs to revert the MPNST phenotype to pNF phenotype. We did this using the following steps:\n\n\n# Select the significantly differentially expressed genes from DEG analysis\ndruid_dge <- MPNSTvsPNF %>% \n  dplyr::select(c(\"logFC\",\"adj.P.Val\")) %>% \n  dplyr::filter(MPNSTvsPNF$adj.P.Val < 0.05)\n  \n# Make query matrix for DRUID\nquery_matrix <- as.matrix(druid_dge)\n\n# Convert the gene names to entrez ids\ngeneSymbols <- AnnotationDbi::mapIds(org.Hs.eg.db, \n                                     keys=rownames(query_matrix), \n                                     column=c(\"ENTREZID\"), \n                                     keytype=\"SYMBOL\", \n                                     multiVals = \"first\") %>% as.data.frame()\n#head(geneSymbols)\nentrez_ids <- geneSymbols$.\n\n# # Run Druid with only significant genes (adj_p_val < 0.05) and save output\n# sig_genes_druid <- concoct(dge_matrix = query_matrix, \n#                            num_random = 10000, \n#                            druid_direction = \"neg\", \n#                            fold_thr = 0.5, \n#                            pvalue_thr = 0.05, \n#                            entrez = entrez_ids)\n# sig_genes_druid_ordered <- sig_genes_druid[order(sig_genes_druid$druid_score, decreasing = TRUE),]\n# #head(sig_genes_druid_ordered)\n# \n# save(sig_genes_druid_ordered, file = \"./sig_genes_druid_mpnst_pnf.RData\")\n\nload(\"./sig_genes_druid_mpnst_pnf.RData\")\n\n\nsig_genes_druid_ordered %>% \n  dplyr::filter(., druid_score > 5) %>% \n  ggplot() + \n  geom_point(aes(x = drug_name, y = cosine_similarity, color = cell_line), alpha = 0.5) + \n  facet_grid(. ~ cell_line, scales = \"free\") + \n  theme_bw() + \n  theme(axis.text.x = element_text(angle = 45))\n\n\n\n\nFigure 2: DRUID predictions for significant DEGs\n\n\n\nThe table below lists all the drugs that were recommended as promising candidates using the DRUID analysis. A higher DRUID score (scale from 0-6) would mean a higher recommendation for the drug compound.\n\n\n{\"x\":{\"filter\":\"none\",\"data\":[[\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\",\"11\",\"12\",\"13\",\"14\",\"15\",\"16\",\"17\",\"18\",\"19\",\"20\",\"21\",\"22\",\"23\",\"24\",\"25\",\"26\",\"27\",\"28\",\"29\",\"30\",\"31\",\"32\",\"33\",\"34\",\"35\",\"36\",\"37\",\"38\",\"39\",\"40\",\"41\",\"42\",\"43\",\"44\",\"45\",\"46\",\"47\",\"48\",\"49\",\"50\"],[\"resveratrol\",\"BRD-K77480336\",\"cisplatin\",\"japonicone a\",\"AZD-6482\",\"monobenzone\",\"etoposide\",\"NSC-95397\",\"palbociclib\",\"palbociclib\",\"HG-5-88-01\",\"selumetinib\",\"etoposide\",\"NVP-AUY922\",\"palbociclib\",\"calmidazolium\",\"NVP-BEZ235\",\"saracatinib\",\"5109870\",\"GW-405833\",\"AZD-8330\",\"methotrexate\",\"ciclopirox\",\"ispinesib\",\"NVP-BEZ235\",\"cladribine\",\"palbociclib\",\"BRD-K60297835\",\"trifluridine\",\"axitinib\",\"KM-03949SC\",\"methotrexate\",\"BRD-K00313977\",\"vemurafenib\",\"BRD-K68548958\",\"spironolactone\",\"methotrexate\",\"BRD-K34092011\",\"lonidamine\",\"0173570-0000\",\"mitoxantrone\",\"decitabine\",\"decitabine\",\"hydroxyachillin\",\"rizatriptan\",\"isotretinoin\",\"CI-976\",\"AZD-6482\",\"ZSTK-474\",\"LY-294002\"],[\"CALCOCO1 up | CENPC up | KLF9 up | MBNL2 up | PIK3IP1 up | TAF9B up | ASPM down | BUB1B down | CCNB1 down | CCNF down | CDC20 down | CDCA8 down | CDK1 down | CENPF down | DLGAP5 down | GTSE1 down | KIF11 down | KIF14 down | KIF20A down | KIFC1 down | MKI67 down | NCAPG down | PLK1 down | RACGAP1 down | UBE2C down\",\"IFI27 up | ASF1B down | ASPM down | BIRC5 down | BLM down | BUB1 down | CCNA2 down | CCNB2 down | CDCA8 down | CDK1 down | CDT1 down | CENPF down | CEP55 down | DLGAP5 down | DTL down | FANCI down | FOXM1 down | GTSE1 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | KIF2C down | LMNB1 down | MCM2 down | MELK down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | RACGAP1 down | RFC2 down | RRM2 down | SPAG5 down | TK1 down | TOP2A down | TPX2 down | TTK down | UBE2C down | ZWINT down\",\"HMGA2 down | TOP2A down | UBE2C down | CCNB2 down | KIF20A down | CDC20 down | PRC1 down | TPX2 down | RACGAP1 down | CDC25B down | ENO1 down | GAPDH down\",\"PPP6C up | ADIRF up | IGFBP6 up | HPS5 up | ARID4A up | TCP11L1 up | RNF125 up | CDC14B up | ISCU up | CCSER2 up | DENND5A up | ZDHHC3 up | WASHC3 up | LGALSL up | FAM117A up | RFC2 down | TOP2A down | MYBL2 down | LPCAT1 down | RRM2 down | FARP1 down | MCM6 down | BIRC5 down | MCM2 down | PLK1 down | BASP1 down | FOXM1 down | CCNB2 down | CDC20 down | LSM5 down | UBE2C down | PAPSS2 down | SPAG5 down | CDK1 down | LMNB1 down | MFAP1 down | CCNA2 down | PTTG1 down | BYSL down | BUB1B down | DLGAP5 down | CA12 down | ZWINT down | DBF4 down | GTSE1 down | KIF11 down | ARHGAP11A down | WDHD1 down | TTK down | MELK down | BLM down | SIX1 down | KIF14 down | APOBEC3B down | KIF2C down | RAB27A down | KIFC1 down | CDT1 down | TPX2 down | EIF3B down | MKI67 down | NCAPH down | FANCI down | CCNB1 down | SKA1 down | EIF2AK1 down | DDX56 down | PRC1 down | NUSAP1 down | ASF1B down | SLC38A1 down | CDCA4 down | TRPS1 down | CEP55 down | DTL down | NCAPG down | KIF20A down | SRD5A3 down | KIF15 down | ASPM down | CDCA8 down | RACGAP1 down\",\"FOXO4 up | APOBEC3B down | ASF1B down | BIRC5 down | CCNA2 down | CDK1 down | CEP55 down | DTL down | KIF20A down | KIF2C down | RRM2 down | UBE2C down | ZWINT down\",\"TCP11L1 up | ARHGAP11A down | ASPM down | AURKA down | CCNB1 down | CCNB2 down | CDC20 down | CENPF down | DLGAP5 down | KIF11 down | KIF14 down | KIF20A down | LMNB1 down | NUSAP1 down | PLK1 down | PTTG1 down | RACGAP1 down | TOP2A down | TPX2 down | TTK down | UBE2C down\",\"KLF9 up | ARHGAP11A down | ASPM down | BUB1B down | CCNA2 down | CCNB1 down | CDC20 down | CENPF down | CEP55 down | DBF4 down | DLGAP5 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | LMNB1 down | MKI67 down | NCAPG down | NCAPH down | PLK1 down | PRC1 down | PTTG1 down | RACGAP1 down | SIX1 down | SPAG5 down | TPX2 down | TTK down | UBE2C down\",\"ABCA8 up | IGFBP6 up | BCAT1 down | P4HA1 down | P4HA2 down | PGK1 down | SEC61G down | SLC16A3 down | SPAG4 down\",\"ALDH1A1 up | PLEKHB1 up | SORBS1 up | TGFBR2 up | ASF1B down | ASPM down | BIRC5 down | BUB1 down | BUB1B down | CA12 down | CCNA2 down | CCNB1 down | CDC20 down | CDC25B down | CDCA8 down | CDK1 down | CENPF down | CEP55 down | DLGAP5 down | FANCI down | FOXM1 down | GTSE1 down | KIF11 down | KIF15 down | KIF20A down | LMNB1 down | MCM6 down | MKI67 down | MYBL2 down | NCAPG down | NUSAP1 down | PLK1 down | PRC1 down | PTTG1 down | RACGAP1 down | RRM2 down | TK1 down | TOP2A down | TPX2 down | UBE2C down | YKT6 down | ZWINT down\",\"ADIRF up | PLEKHB1 up | ASF1B down | ASPM down | BIRC5 down | BUB1 down | BUB1B down | CA12 down | CCNA2 down | CDC20 down | CDC25B down | CDCA8 down | CDK1 down | CDT1 down | CENPF down | CEP55 down | DLGAP5 down | DTL down | E2F2 down | FANCI down | FOXM1 down | GTSE1 down | KIF11 down | KIF15 down | KIF20A down | KIFC1 down | LMNB1 down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | PTTG1 down | RACGAP1 down | RRM2 down | SDC1 down | TK1 down | TOP2A down | TPX2 down | TTK down | UBE2C down | YKT6 down | ZWINT down\",\"ARHGEF6 up | CHL1 up | ERBB3 up | IGFBP6 up | S100B up | CDCA4 down | CYP27B1 down | HMGA2 down | PAPSS2 down\",\"ABCA8 up | ADIRF up | BDH2 up | EFHC1 up | FAXDC2 up | FOXO4 up | GPM6B up | GSN up | IFI27 up | METTL7A up | PDCD4 up | PLEKHB1 up | AGO2 down | APOBEC3B down | ASF1B down | BASP1 down | BOP1 down | CCNA2 down | CCNB2 down | CCNF down | CDCA4 down | CDK1 down | CEP55 down | DTL down | GAL down | GALNT14 down | GTSE1 down | HMGA2 down | HSPH1 down | KIF14 down | KRT18 down | MKI67 down | MYBL2 down | NCAPG down | PMAIP1 down | RAD51 down | RFC2 down | RRM2 down | SRPK1 down | TPX2 down | UBE2C down | ZWINT down\",\"METTL7A up | TCP11L1 up | ASPM down | BUB1B down | CCNA2 down | CCNB1 down | CDC20 down | CDCA8 down | CENPF down | CEP55 down | CHRNA5 down | DLGAP5 down | DTL down | KIF11 down | KIF14 down | KIF20A down | KIF2C down | LMNB1 down | NCAPG down | PLK1 down | PRC1 down | TPX2 down | UBE2C down\",\"EFCAB14 up | ADGRG6 up | MBNL2 up | NF1 up | ASF1B down | BOP1 down | BYSL down | CDCA4 down | CHODL down | DTL down | EEF1A2 down | ENO1 down | MCM2 down | MCM6 down | MYBL2 down | NOP56 down | RRM2 down | TK1 down | ZWINT down\",\"ADIRF up | APOBEC3B down | ASF1B down | ASPM down | AURKA down | BIRC5 down | BUB1 down | BUB1B down | CCNA2 down | CCNF down | CDK1 down | CENPF down | CEP55 down | DBF4 down | DLGAP5 down | FOXM1 down | GTSE1 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | LMNB1 down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PRC1 down | RACGAP1 down | RRM2 down | SKA1 down | SPAG5 down | TOP2A down | TPX2 down | TTK down | UBE2C down | YKT6 down\",\"ALDH1A1 up | KLF9 up | SERPINB4 down | SERPINI1 down\",\"ERBB3 up | MBNL1 up | CAVIN2 up | SPTBN1 up | TGFBR2 up | ASF1B down | ASPM down | AURKA down | BIRC5 down | BUB1 down | CA12 down | CCNA2 down | CCNB2 down | CDC20 down | CDCA4 down | CDK1 down | CENPF down | CEP55 down | DLGAP5 down | FOXM1 down | KIF11 down | KIF15 down | KIF20A down | LMNB1 down | MELK down | MYBL2 down | PRC1 down | PTTG1 down | RACGAP1 down | RRM2 down | SLPI down | TK1 down | TOP2A down | TPX2 down | UBE2C down | YKT6 down | ZWINT down\",\"BIRC5 down | CDC20 down | EEF1A2 down | HAPLN1 down | PTTG1 down | SH3BGRL3 down | SLC16A3 down | TOMM34 down | UBE2C down\",\"ASPM down | BUB1B down | CCNB1 down | CCNF down | CDC20 down | CDCA8 down | CENPF down | DLGAP5 down | GTSE1 down | KIF11 down | KIF14 down | KIF20A down | KIFC1 down | MKI67 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | RACGAP1 down | TOP2A down | TPX2 down | TTK down | UBE2C down\",\"FGL2 up | ASPM down | AURKA down | BIRC5 down | BUB1 down | CCNA2 down | CCNF down | CDK1 down | CENPF down | CEP55 down | DLGAP5 down | DLK1 down | DTL down | FANCI down | GTSE1 down | KIF11 down | KIF14 down | KIF20A down | LMNB1 down | MCM2 down | MCM6 down | MKI67 down | NCAPG down | NUSAP1 down | PLK1 down | RRM2 down | TOP2A down | TPX2 down | ZWINT down\",\"ADIRF up | ALDH1A1 up | WASHC3 up | DNAJC15 up | GSN up | IFI27 up | IFIT1 up | METTL7A up | PDCD4 up | RASSF2 up | TCEAL4 up | ASF1B down | ASPM down | AURKA down | BIRC5 down | BUB1 down | CCNA2 down | CCNB2 down | CCNF down | CDC20 down | CDK1 down | CEP55 down | DBF4 down | DLGAP5 down | DTL down | EREG down | FOXM1 down | GTSE1 down | HMGA2 down | KIF11 down | KIF14 down | KIF20A down | LMNB1 down | MCM2 down | MCM6 down | MELK down | MKI67 down | MYBL2 down | NCAPG down | NUSAP1 down | PLK1 down | PRC1 down | RACGAP1 down | RAD51 down | RFC2 down | RRM2 down | TOP2A down | TPX2 down | UBE2C down | YKT6 down | ZWINT down\",\"NF1 up | ARHGAP11A down | ASPM down | AURKA down | BUB1B down | CCNB1 down | CDC20 down | CDCA8 down | CENPF down | DBF4 down | DLGAP5 down | ENTPD7 down | KIF11 down | KIF14 down | KIF20A down | LMNB1 down | PLK1 down | PRC1 down | TOP2A down | TPX2 down | TTK down | UBE2C down\",\"PIK3IP1 up | ARHGAP11A down | ARMC4 down | ASPM down | AURKA down | BUB1B down | CCNB1 down | CDC20 down | CDC25B down | CDCA8 down | CENPF down | DLGAP5 down | KIF11 down | KIF14 down | KIF20A down | MKI67 down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | RACGAP1 down | TOP2A down | TPX2 down | UBE2C down\",\"IFI27 up | IFI35 up | IFIT2 up | IFIT3 up | RRM2 down\",\"CALCOCO1 up | ERBB3 up | FAXDC2 up | FOXO4 up | IGFBP7 up | PIK3IP1 up | AGT down | CCNA2 down | CDK1 down | DTL down | ENO1 down | GALE down | LMNB1 down | MCM6 down | MELK down | P4HB down | RFC2 down | RRBP1 down | RRM2 down | SLPI down | ZWINT down\",\"ASPM down | AURKA down | BUB1 down | CCNA2 down | CCNF down | CDC20 down | CDC25B down | CDCA8 down | CDK1 down | CENPF down | CEP55 down | DLGAP5 down | GTSE1 down | KIF11 down | KIF14 down | KIF20A down | KIF2C down | KIFC1 down | LMNB1 down | MKI67 down | NCAPG down | PLK1 down | PTTG1 down | TOP2A down | TPX2 down | TTK down | UBE2C down\",\"ADIRF up | GSN up | IFI27 up | APOBEC3B down | ASF1B down | ASPM down | AURKA down | BIRC5 down | BUB1 down | BUB1B down | CCNA2 down | CCNB1 down | CCNB2 down | CCNF down | CDCA8 down | CDK1 down | CDT1 down | CENPF down | CEP55 down | DLGAP5 down | DTL down | FANCI down | FOXM1 down | GTSE1 down | HSPH1 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | KIFC1 down | LMNB1 down | MELK down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | PTTG1 down | RACGAP1 down | RRM2 down | SPAG5 down | TOP2A down | TPX2 down | TTK down | UBE2C down | YKT6 down\",\"ADD3 up | FAXDC2 up | IFI27 up | ORC1 down\",\"HFE up | MBNL2 up | NF1 up | RAPGEF2 up | ASPM down | AURKA down | BUB1B down | CCNB1 down | CCNF down | CDC20 down | CDCA8 down | DLGAP5 down | KIF14 down | KIF20A down | KIFC1 down | LMNB1 down | PLK1 down | PRC1 down | TPX2 down | TTK down | UBE2C down\",\"ASPM down | CCNA2 down | CCNB2 down | CCNF down | CDK1 down | CENPF down | DTL down | GTSE1 down | KIF14 down | KIF20A down | MELK down | MMP10 down | NUSAP1 down | PLK1 down | PRC1 down | TOP2A down | UBE2C down\",\"GAB2 up | TGFBR2 up | CA9 down | EEF1A2 down | NUSAP1 down | SNCAIP down\",\"FAXDC2 up | TCP11L1 up | ASPM down | AURKA down | CCNB1 down | CDC20 down | CDCA8 down | CENPF down | CYP26A1 down | DBF4 down | DLGAP5 down | KIF11 down | KIF14 down | KIF20A down | PLK1 down | TPX2 down | UBE2C down\",\"CDC14B up | IGFBP7 up | ZEB2 up | CDCA4 down | LPCAT1 down | SDC1 down | SLPI down\",\"ABCA8 up | BDH2 up | CTSO up | GPM6B up | GSN up | IFI27 up | IFIT1 up | IGFBP7 up | METTL7A up | PLEKHB1 up | DTL down | MMP9 down | NOP56 down | RRM2 down\",\"GSN up | IFI27 up | IFIT1 up | IFIT3 up | MBNL2 up | APOBEC3B down | ASF1B down | ASPM down | AURKA down | BIRC5 down | BUB1 down | BUB1B down | CCNA2 down | CCNB2 down | CCNF down | CDCA4 down | CDCA8 down | CDK1 down | CDT1 down | CENPF down | CEP55 down | DLGAP5 down | DTL down | FANCI down | FOXM1 down | GTSE1 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | KIF2C down | LMNB1 down | MCM6 down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | RACGAP1 down | RAD51 down | RFC2 down | RRM2 down | SPAG5 down | TK1 down | TOP2A down | TPX2 down | TTK down | ZWINT down\",\"ASPM down | BIRC5 down | CCNA2 down | CDCA4 down | CDK1 down | CENPF down | DLGAP5 down | DTL down | FANCI down | FOXM1 down | KIF14 down | KIF15 down | KIF20A down | MCM6 down | MELK down | MYBL2 down | NUSAP1 down | PRC1 down | PTTG1 down | RACGAP1 down | RAD51 down | RRM2 down | TPX2 down | ZWINT down\",\"FAXDC2 up | ASPM down | CCNB1 down | CCNF down | CDC20 down | CDCA8 down | DLGAP5 down | EGLN3 down | KIF14 down | KIF20A down | KIFC1 down | MKI67 down | PLK1 down | TOP2A down | TPX2 down | UBE2C down\",\"WASHC3 up | EFHC1 up | NR2F2 up | EIF3B down | RRBP1 down\",\"FGL2 up | CCNA2 down | CCNB1 down | DTL down | GTSE1 down | MCM6 down | MKI67 down | RRM2 down | TOP2A down | ZWINT down\",\"DLC1 up | PHLDB1 up | ASPM down | CCNA2 down | CCNB1 down | CCNB2 down | CDC20 down | CDC25B down | CDCA8 down | CENPF down | CENPO down | DBF4 down | DLGAP5 down | KIF11 down | KIF14 down | KIF20A down | KIF2C down | PLK1 down | PRC1 down | PRR3 down | TPX2 down\",\"ADIRF up | PIK3IP1 up | ALDH1A2 down | APOBEC3B down | ASF1B down | ASPM down | AURKA down | BIRC5 down | BLM down | BUB1 down | CA12 down | CCNA2 down | CCNB2 down | CCNF down | CDC20 down | CDCA8 down | CDK1 down | CDT1 down | CENPF down | CEP55 down | CHODL down | DBF4 down | DLGAP5 down | DLK1 down | DTL down | FANCI down | FOXM1 down | GAL down | GTSE1 down | KIF11 down | KIF14 down | KIF15 down | KIF20A down | KIFC1 down | LMNB1 down | MCM2 down | MCM6 down | MELK down | MKI67 down | MYBL2 down | NCAPG down | NCAPH down | NUSAP1 down | PLK1 down | PRC1 down | PTTG1 down | RACGAP1 down | RAD51 down | RFC2 down | RRM2 down | SLC39A8 down | SPAG5 down | TK1 down | TOP2A down | TPX2 down | TTK down | UBE2C down | YKT6 down | ZWINT down\",\"VAMP3 up | IFT57 up | DENND5A up | SPTBN1 up | ADGRG6 up | GPD1L up | IGFBP6 up | GSN up | FBXL5 up | LBH down | LSM5 down | RRM2 down | MELK down | DBF4 down | TOP2A down | RACGAP1 down | PTTG1 down | NOP56 down | MCM6 down | TUBA1C down | HSPD1 down | ENO1 down | TPI1 down | CA12 down | CTSL down | EREG down | CXCL5 down\",\"HEPH up | GALNT14 down | KIF15 down | KIF11 down | CEP55 down | DLGAP5 down | MKI67 down | BLM down | SLC39A8 down\",\"IFIT5 up | NDRG2 up | NR3C2 up | ZNF32 up | CHRNA9 down | MMP9 down | P4HA2 down\",\"ABLIM3 up | KLF9 up | MBNL1 up | METTL7A up | CAVIN2 up | PRAME down\",\"ADD3 up | ARHGAP12 up | CCSER2 up | METTL7A up | SLC48A1 up | BCL11A down | SLC16A10 down | TOMM34 down\",\"IFIT2 up | IFIT3 up | IFIT5 up | ITGA6 up | PHF11 up | CCNA2 down | KIF20A down | LBH down | PROM1 down\",\"CA12 down | EDN3 down | GPR88 down\",\"CBX7 up | METTL7A up | BIRC5 down | CDC20 down | CDK1 down | DTL down | ENO1 down | LSM5 down | PFKP down | PGK1 down | SEC61G down | SLC16A3 down | SPAG4 down | UBE2C down\",\"CBX7 up | ITIH5 up | GAL down | MYBL2 down | SLPI down\"],[6,6,6,6,5.97644413321826,5.97189639469091,5.92732245949397,5.89099765319512,5.8211568487067,5.80692136104245,5.8022399605357,5.80012805369111,5.7967685612053,5.77145532356961,5.76138449262258,5.71109733470728,5.71007417511606,5.70928221641506,5.70698481560387,5.7025646547974,5.70052030046444,5.69347636509199,5.69022154255753,5.68792203004462,5.67443559938898,5.66609001891276,5.66273217512166,5.66002118652896,5.65630961805763,5.64717660318792,5.64284815484804,5.64040842162511,5.63671125151081,5.63506741805526,5.62762275230069,5.62367891302842,5.61676818313013,5.61000623986201,5.60493322533054,5.59513772096328,5.58405822433728,5.58392268853473,5.539008776472,5.50613915273768,5.42597776857855,5.40777198688724,5.38057490861936,5.37512097224707,5.36219997411365,5.33702127814081],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0001,0,0.0001,0,0,0.0001,0,0,0,0,0,0,0.0001,0,0.0001,0,0,0.0001,0.0001,0,0.0001,0,0.0001,0,0,0.0001,0.0001,0,0,0.0002,0,0.0002,0.0002,0.0002,0.0002],[\"MCF7\",\"MCF7\",null,\"MCF7\",\"VCAP\",\"MCF7\",\"MCF7\",\"HA1E\",\"LNCAP\",\"LNCAP\",\"HME1\",\"A375\",\"MCF7\",\"VCAP\",\"PC3\",\"HT29\",\"HEPG2\",\"ASC\",\"MCF7\",\"HCC515\",\"MCF10A\",\"MCF7\",\"MCF7\",\"SKB\",\"MCF7\",\"VCAP\",\"A375\",\"PC3\",\"MCF7\",\"MCF7\",\"HA1E\",\"MCF7\",\"HCC515\",\"A375\",\"HCC515\",\"VCAP\",\"MCF7\",\"MCF7\",\"HCC515\",\"PC3\",\"MCF7\",null,null,\"HL60\",\"A549\",\"HL60\",\"HA1E\",\"SKBR3\",\"ASC\",\"PC3\"]],\"container\":\"<table class=\\\"display\\\">\\n  <thead>\\n    <tr>\\n      <th> <\\/th>\\n      <th>drug_name<\\/th>\\n      <th>matched_genes<\\/th>\\n      <th>druid_score<\\/th>\\n      <th>probability_random<\\/th>\\n      <th>cell_line<\\/th>\\n    <\\/tr>\\n  <\\/thead>\\n<\\/table>\",\"options\":{\"columnDefs\":[{\"className\":\"dt-right\",\"targets\":[3,4]},{\"orderable\":false,\"targets\":0}],\"order\":[],\"autoWidth\":false,\"orderClasses\":false}},\"evals\":[],\"jsHooks\":[]}\n\n\n\nDistill is a publication format for scientific and technical writing, native to the web.\nLearn more about using Distill for R Markdown at https://rstudio.github.io/distill.\n\n\n\n",
      "last_modified": "2021-11-04T17:44:08-07:00"
    },
    {
      "path": "index.html",
      "title": "Sage Bionetworks NF-OSI Research",
      "description": "This website hosts various analyses done on NF related data available on the [NF Data Portal](www.nfdataportal.org)\n",
      "author": [],
      "contents": "\n\n\n\n",
      "last_modified": "2021-11-04T17:44:08-07:00"
    },
    {
      "path": "rfc-brief.html",
      "title": "Data sharing specifications for the NF community",
      "description": "Status: **Proposed standard**\n",
      "author": [
        {
          "name": "Robert Allaway",
          "url": "https://github.com/allaway"
        },
        {
          "name": "Jineta Banerjee",
          "url": "https://github.com/jaybee84"
        },
        {
          "name": "Anh Nguyet Vu",
          "url": "https://github.com/anngvu"
        },
        {
          "name": "<\/br><span class = \"custom-heading\">Community Contributors<\/span><\/br>\n",
          "url": {}
        },
        {
          "name": "Larry Benowitz, Joanne Ngeow, Vincent Riccardi, Scott Plotkin, Jianqiang Wu, Angela C. Hirbe, Filipa Jorge Teixeira, Shruti Garg, Rianne Oostenbrink, Bruce Korf, Hui Liu, Adrienne L. Watson, Parnal Joshi, Tom Reh, Eva Trevisson",
          "url": {}
        }
      ],
      "date": "2021-12-01",
      "contents": "\n\nContents\nAbstract\nIntroduction\nData types and formats summary\nAdditional considerations\nImaging data\nClinical data\nAlternative assay/platform data\n\nRFC statistics\nRespondent profiles\nSurvey quantified responses\n\n\nAbstract\nThe NF Data Portal community is dedicated towards bringing the latest data and research from the NF research community to the world. In doing so the Portal maintains and implements FAIR standards to make various types of research data findable, accessible, interoperable and reusable. Recently the Portal community reached out to the research community asking feedback regarding sharing logistics of various data types and their file formats. This document describes data types and formats that should be shared by the Neurofibromatosis (NF) research community for the NF Data Portal.\nIntroduction\nThe NF Data Portal is a collaborative data-sharing platform for Neurofibromatosis, a rare genetic disease (Allaway et al. 2019). It has been jointly supported by multiple funding organizations â the Gilbert Family Foundation (GFF), Childrenâs Tumor Foundation (CTF), Neurofibromatosis Therapeutic Acceleration Program (NTAP), NCI Developmental and Hyperactive Ras Tumor SPORE (DHART SPORE), CDMRP Neurofibromatosis Research Program (CDMRP NFRP), and Neurofibromatosis Research Initiative (NFRI) â and therefore represents substantial NF research activity.\nAs the NF Data Portal community continues to expand to add newly affiliated as well as independent researchers, and therefore new data, having these standards will help maintain the quality and quantity of our valuable resources. But also important is that this document should actually benefit our data contributors.  One advantage is allowing our contributors to prioritize submissions accordingly. As well, our contributors have a clear reference for the data formats that are preferred for sharing. These specifications should lead to higher-impact data through encouraging interoperable formats that make data more likely to be reused (and cited). Finally, this open document lets our community be informed of the current state of art, including specifications currently not included, so that they can provide input towards specific/new data formats.\nThe data-sharing specifications highlighted in this document have been informed by members in the research community, using their opinions solicited through an open Request for Comments (RFC). The feedback received from the community was especially influential for data types outside of what is required by default, i.e.Â more âoptionalâ data types. These specifications also follow requirements already established by the NF-OSI funding organizations, which apply to data types with clear âreusabilityâ value and for which there are well-defined strategies for sharing (e.g.Â sequencing data). Journal requirements and other repositories were considered to a much lesser extent.\nData types and formats summary\nAs a representation of the most recent funder requirements and RFC results, table 1 summarizes specifications for common data types that are of interest for the NF community. These standards should apply for most general cases. However, we do note that for some data types, the community provided additional considerations that serve to qualify or supplement what is in this table (see Additional considerations). This qualitative feedback point to certain data domains that may need deeper evaluation. Alongside the qualitative results, quantitative breakdowns for components of the RFC are available (see RFC statistics).\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#lsvmvbmwyw .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 14px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#lsvmvbmwyw .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 6px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#lsvmvbmwyw .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#lsvmvbmwyw .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#lsvmvbmwyw .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#lsvmvbmwyw .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#lsvmvbmwyw .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#lsvmvbmwyw .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #FFEFDB;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#lsvmvbmwyw .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFEFDB;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#lsvmvbmwyw .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#lsvmvbmwyw .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#lsvmvbmwyw .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#lsvmvbmwyw .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#lsvmvbmwyw .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lsvmvbmwyw .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lsvmvbmwyw .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#lsvmvbmwyw .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#lsvmvbmwyw .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#lsvmvbmwyw .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#lsvmvbmwyw .gt_left {\n  text-align: left;\n}\n\n#lsvmvbmwyw .gt_center {\n  text-align: center;\n}\n\n#lsvmvbmwyw .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#lsvmvbmwyw .gt_font_normal {\n  font-weight: normal;\n}\n\n#lsvmvbmwyw .gt_font_bold {\n  font-weight: bold;\n}\n\n#lsvmvbmwyw .gt_font_italic {\n  font-style: italic;\n}\n\n#lsvmvbmwyw .gt_super {\n  font-size: 65%;\n}\n\n#lsvmvbmwyw .gt_footnote_marks {\n  font-style: italic;\n  font-weight: normal;\n  font-size: 65%;\n}\nTable 1: Specifications for relevant common data types.\n  \n  \n      Requirement\n      Levelsa\n      Format\n      Notes\n    DNA\n    whole genome sequencing\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\nwhole exome sequencing\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\nSNP microarray\nrequired\nraw AND processed\n\nraw: CEL, IDAT, tsv (raw values per SNP) & processed: tsv (genotypes per SNP)\nimmunosequencing\nrequired\nraw OR semi-processed\n\nvendor-dependent, e.g. ImmunoSEQ and 10XGenomics formats\nSanger sequencing\noptional\nprocessed\n\n\nRNA expression\n    RNA sequencing (bulk or single-cell)\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\ngene expression microarray\nrequired\nraw AND processed\n\nraw: CEL, IDAT, tsv (raw values per SNP, copy number, and loss of heterozygosity) & processed: tsv (normalized values and purity/ploidy)\nqPCR\noptional\nprocessed\n\ncsv/tsv (according to template)\nmethylation\n    ATAC sequencing\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\nmethylation array\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\nbisulfite sequencing\nrequired\nraw OR semi-processed\n\nraw: FASTQ, unaligned BAM, CRAM | semi-processed: aligned BAM\nprotein\n    LC-MS\nrequired\nraw AND processed\n\nraw: mzML & processed: protein intensities (csv/tsv)\nhttps://www.psidev.info/mzMLwestern blot\noptional\nprocessed\n\ndensitometry output (csv/tsv)\nplate-based ELISA\noptional\nraw\n\nplate reader output (csv/tsv)\nprotein/peptide microarrays\nrequired\nprocessed\n\nlabel-free quantification matrix (csv/tsv)\nmetabolomics\n    LC-MS\nrequired\nraw AND processed\n\nraw: mzML or vendor-dependent format & processed: metabolite intensities (csv/tsv)\nclinical\n    structured clinical data\nrequired\nprocessed\n\ncsv/tsv or XML with metadata for each variable\nkey primary and secondary endpoints onlyEEG\nrequired\nraw\n\n\npending additional commentsclinical/imaging\n    MRI or other radiological image\nrequired\nraw\n\ndicom, nifti, minc\nimaging\n    immunohistochemistry\nrequired\nraw\n\ntiff, ome-tiff\nimmunofluorescence\nrequired\nraw\n\ntiff, ome-tiff\ngross morphology photos (mice)\noptional\nraw\n\ntiff, png, jpg\nin vitro drug screening\n    plate-based cell viability assay\nrequired\nprocessed\n\ncsv/tsv (according to template)\nother\n    flow cytometry\noptional\nraw\n\nfsc with gating parameters\nin vivo tumor growth experiments\noptional\nraw OR processed\n\ncsv/tsv (according to template) where raw: tumor dimensions or other raw measurements & processed: calculated tumor volume/size\n\n        \n          a\n          \n           \n          Level nomenclature can be cross-referenced with https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/data-levels, where 'raw' corresponses to Level 1 and 'semi-processed' most closely corresponds to Level 2.\n          \n      \n    \n\nAdditional considerations\n\nThe current specifications should guide contributions in the âspirit of effective data sharingâ and are most applicable when they lead to intended results, e.g.Â higher-impact shared data and reasonable balance of contributor/administrative effort given the expected value of the data shared.  But there can be debatable cases where a ârequiredâ specification is less applicable. The community has anticipated issues like these and provided recommendations for some of them. However, difficult and unclear cases remain or may yet emerge, which will need more community consensus still. \nImaging data\nComments from the community noted two possible issues for imaging data.\nA first question is whether imaging data should be shared when there are at most only a few images, which is of limited utility for re-analysis (e.g.Â with machine learning) usually requiring a large set of images. That is, imaging data may require a âcritical mass.â When only a few images are contributed, these are likely only representative images that might also appear in a publication. In this case, it may not be really ârequiredâ that these images have to be shared.\nA second case is for a study that may generate many images but can only process and fully annotate a subset. For example, there can be a large number of pathology images without any annotations of disease features by a pathologist, as these kinds of annotations are manually intensive. If all data are expected to be annotated â and annotations are especially important for the usefulness of the images â the question arises whether images outside the fully annotated subset should be shared. A clear suggestion seems to be that sharing images without annotations is better than not sharing images â for some images, it is possible for someone else to go back and add annotations. Note that basic, automatic annotations are still expected; using the example above, the images should still have an associated sample ID and tissue source.\nClinical data\nClinical data can be extremely diverse and unstructured. While we have incorporated comments for structured clinical data, we have not received comments for unstructured clinical data such as patient histories that are often captured in text reports. Clinical data still remains very open to comment from those in the community.\nAlternative assay/platform data\nThe specifications table includes the most common assay data types instead of enumerating all variants or alternatives. An insightful community observation suggested there can be less common but better alternatives for some assays. The example given was using a WES capillary protein analysis system in lieu of traditional western blot for easier analysis as well as raw data sharing.\nThis is actually asking a different design question â not necessarily âWhat level and format of data should be used for better sharing?â but âWhat assays/platform should be used for better sharing?â It is certainly not within our purview to specify what should be used, and experiments will have to be planned around what assays the researchers are familiar with and what equipment is available. We are also aware that researchers are not likely to think about data sharing specifications until results have been generated, while this kind of consideration would take place before experiments even start. Nevertheless, if the investigator is at the juncture of a design decision, awareness of alternatives and their relative merit in terms of data sharing could be helpful.  Unfortunately, this aspect is not captured well in our current specifications. We welcome the community providing more suggestions in this regard. \nRFC statistics\nRespondent profiles\n\n\n\nFigure 1: Demographic representation of RFC community respondents\n\n\n\nFigure 1 summarizes the representation of different demographic types as self-reported through the question âWhat âtypeâ of NF research community member are you?â Because respondents could indicate more than one demographic type, a statistic of 43% here should be interpreted to mean that 43% of the responses represented the clinician perspective. Overall, the RFC garnered highest representation from bench scientists and clinicians, which was expected. That clinicians had nearly as much representation as bench scientists likely reflects the highly translational focus of the NF Data Portal community relative to more general data repositories.\nIn the RFC, we did not distinguish whether respondents considered themselves more a âdata contributor,â a âdata re-userâ or possibly âequally both.â In the future, this additional facet may provide additional insight in case there are conflicts in perspectives between these profiles.  \n\nSurvey quantified responses\n\n\n\nFigure 2 summarizes responses to the question âShould it be required to deposit raw data?â for the different assay or different type categories. There were four categories that reached majority consensus for sharing: in vivo growth tumor data, Sanger sequencing, structured clinical data, and western blot.\n\n\n\nFigure 2: Survey responses for whether depositing raw data should be required for different assays\n\n\n\nFigure 3 summarizes responses to the question âHave you ever re-analyzed this type of data, or wanted to, if the right dataset existed?â for the different assay or different type categories. The highest interest was for structured clinical data, which also garnered the strongest consensus that it should be shared (Fig 2).\n\n\n\nFigure 3: Survey responses for previous experience or interest in re-analyzing data for different assays\n\n\n\nFigure 4 summarizes responses to the question âHave you previously been required to share a complete raw dataset by a funder or journal?â The responses suggest that funder or journal sharing requirements for these assays or data types are not common, except for perhaps structured clinical data and western blots. Compared to ratings in Fig 2, the results here also suggest that the community is willing to go beyond the âbaselineâ requirements of funders or journals.\n\n\n\nFigure 4: Survey responses for previous requirements to share raw data by a funder or journal\n\n\n\n\n\n\nAllaway, Robert J., Salvatore La Rosa, Sharad Verma, Lara Mangravite, Justin Guinney, Jaishri Blakeley, Annette Bakker, and Sara J. C. Gosline. 2019. âEngaging a Community to Enable Disease-Centric Data Sharing with the NF Data Portal.â Scientific Data 6 (1): 319. https://doi.org/10.1038/s41597-019-0317-x.\n\n\n\n\n",
      "last_modified": "2021-12-06T08:45:00-08:00"
    }
  ],
  "collections": []
}
